Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.

Karen S Aboody; Joseph Najbauer; Nils-Ole Schmidt; Wendy Yang; Julian K Wu; Yuzheng Zhuge; Wojciech Przylecki; Rona Carroll; Peter M Black; George Perides

Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.

Standard

Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. / Aboody, Karen S; Najbauer, Joseph; Schmidt, Nils-Ole; Yang, Wendy; Wu, Julian K; Zhuge, Yuzheng; Przylecki, Wojciech; Carroll, Rona; Black, Peter M; Perides, George.

In: NEURO-ONCOLOGY, Vol. 8, No. 2, 2, 2006, p. 119-126.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Aboody, KS, Najbauer, J, Schmidt, N-O, Yang, W, Wu, JK, Zhuge, Y, Przylecki, W, Carroll, R, Black, PM & Perides, G 2006, 'Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.', NEURO-ONCOLOGY, vol. 8, no. 2, 2, pp. 119-126. <http://www.ncbi.nlm.nih.gov/pubmed/16524944?dopt=Citation>

APA

Aboody, K. S., Najbauer, J., Schmidt, N-O., Yang, W., Wu, J. K., Zhuge, Y., Przylecki, W., Carroll, R., Black, P. M., & Perides, G. (2006). Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. NEURO-ONCOLOGY, 8(2), 119-126. [2]. http://www.ncbi.nlm.nih.gov/pubmed/16524944?dopt=Citation

Vancouver

Aboody KS, Najbauer J, Schmidt N-O, Yang W, Wu JK, Zhuge Y et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. NEURO-ONCOLOGY. 2006;8(2):119-126. 2.

Bibtex

@article{bd29fbd6c7d54fcba4d068bffa5ce8df,

title = "Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.",

abstract = "Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases.",

author = "Aboody, {Karen S} and Joseph Najbauer and Nils-Ole Schmidt and Wendy Yang and Wu, {Julian K} and Yuzheng Zhuge and Wojciech Przylecki and Rona Carroll and Black, {Peter M} and George Perides",

year = "2006",

language = "Deutsch",

volume = "8",

pages = "119--126",

journal = "NEURO-ONCOLOGY",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "2",

}

RIS

TY - JOUR

T1 - Targeting of melanoma brain metastases using engineered neural stem/progenitor cells.

AU - Aboody, Karen S

AU - Najbauer, Joseph

AU - Schmidt, Nils-Ole

AU - Yang, Wendy

AU - Wu, Julian K

AU - Zhuge, Yuzheng

AU - Przylecki, Wojciech

AU - Carroll, Rona

AU - Black, Peter M

AU - Perides, George

PY - 2006

Y1 - 2006

N2 - Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases.

AB - Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases.

M3 - SCORING: Zeitschriftenaufsatz

VL - 8

SP - 119

EP - 126

JO - NEURO-ONCOLOGY

JF - NEURO-ONCOLOGY

SN - 1522-8517

IS - 2

M1 - 2

ER -